The Current Achievements and Existing Shortage of Immune Checkpoint Inhibitor
DOI:
https://doi.org/10.54097/y3tbyr95Keywords:
Immune checkpoint, immune checkpoint inhibitors (ICI), immune tolerance.Abstract
Immune checkpoint inhibitor (ICI) is drug used to treat cancer by blocking immune checkpoint molecules and activating the immune system to attack tumor cells. ICI has limitations, including varying patient immune tolerance, immune-related adverse events, and unclear biomarkers. However, it is currently the most widely used, versatile, and highly effective immunotherapy drug. By comparing the efficacy of ICI with other treatment methods and citing examples of its breakthrough role in different cancers, the superiority of ICI is demonstrated. At the same time, it still has great potential and clinical value in the field of immunotherapy, and there is great room for development in both the design of new targets and the new application of known targets. This article discusses the advantages of ICI, particularly when combined with radio chemotherapy and chemotherapy, in cancer treatment. The summary outlines its mechanism of action, current applications, achievements, and limitations in the field further needed to be addressed.
Downloads
References
Scott EC, Baines AC, Gong Y, Moore R Jr, Pamuk GE, Saber H, Subedee A, Thompson MD, Xiao W, Pazdur R, Rao VA, Schneider J, Beaver JA. Trends in the approval of cancer therapies by the FDA in the twenty-first century. Nat Rev Drug Discov. 2023 Aug; 22 (8): 625-640.
Harding J J, Moreno V, Bang Y J, et al. Blocking TIM-3 in treatment refractory advanced solid tumors: a phase 1a/b study of LY3321367 with or without an anti-PD-L1 antibody [J]. Clin Cancer Res, 2021, 27 (8): 2168-2178.
Sun Q, Hong Z, Zhang C, Wang L, Han Z, Ma D. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal Transduct Target Ther. 2023 Aug 28; 8 (1): 320.
Yadav R, Hakobyan N, Wang JC. Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature. Int J Mol Sci. 2023 Aug 7; 24 (15): 12502.
Shang S, Zhao Y, Qian K, Qin Y, Zhang X, Li T, Shan L, Wei M, Xi J, Tang B. The role of neoantigens in tumor immunotherapy. Biomed Pharmacother. 2022 Jul; 151: 113118.
Liu Z, Ning F, Cai Y, Sheng H, Zheng R, Yin X, Lu Z, Su L, Chen X, Zeng C, Wang H, Liu L. The EGFR-P38 MAPK axis up-regulates PD-L1 through miR-675-5p and down-regulates HLA-ABC via hexokinase-2 in hepatocellular carcinoma cells. Cancer Commun (Lond). 2021 Jan; 41 (1): 62-78.
Shrestha R, Bridle KR, Crawford DHG, Jayachandran A. Immune checkpoint molecules are regulated by transforming growth factor (TGF)-β1-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma. Int J Med Sci. 2021 Apr 22; 18 (12): 2466-2479.
Hou W, Yi C, Zhu H. Predictive biomarkers of colon cancer immunotherapy: Present and future. Front Immunol. 2022 Nov 22; 13: 1032314.
Li Yingying, Li Jinhu, Liu Xiaodong Research progress of radiotherapy combined with immune checkpoint inhibitors in the treatment of glioblastoma Cancer Prevention Research 2022, 49 (05): 490-495. DOI: 10.3971/j.issn.1000-8578.21.21.1069
Li S, Yu W, Xie F, Luo H, Liu Z, Lv W, Shi D, Yu D, Gao P, Chen C, Wei M, Zhou W, Wang J, Zhao Z, Dai X, Xu Q, Zhang X, Huang M, Huang K, Wang J, Li J, Sheng L, Liu L. Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. Nat Commun. 2023 Jan 3; 14 (1): 8.
Park S, Ock CY, Kim H, Pereira S, Park S, Ma M, Choi S, Kim S, Shin S, Aum BJ, Paeng K, Yoo D, Cha H, Park S, Suh KJ, Jung HA, Kim SH, Kim YJ, Sun JM, Chung JH, Ahn JS, Ahn MJ, Lee JS, Park K, Song SY, Bang YJ, Choi YL, Mok TS, Lee SH. Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 Jun 10; 40 (17): 1916-1928.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
